Epigenetic Reprogramming and Age Reversal: The First Human Trial Has Begun

What if the reason you’re ageing isn’t because your body is breaking down — but because your cells have forgotten how to stay young? That’s the question driving a new wave of longevity science, and in January 2026, it moved from theory to reality. A Boston biotech called Life Biosciences received FDA clearance to begin the first ever human trial of epigenetic reprogramming — a gene therapy designed not to slow ageing, but to reverse it at the cellular level.

This isn’t another supplement or lifestyle hack. It’s a direct attempt to reset your cells’ biological clock. And whether or not it works, this trial marks a turning point in how medicine thinks about age-related disease.

Key Takeaways

• Life Biosciences has launched the first human clinical trial of a cellular rejuvenation therapy using partial epigenetic reprogramming — a historic first.
• The therapy, ER-100, uses three Yamanaka factors (OSK) to reset the epigenetic age of cells without converting them back into stem cells.
• Animal studies showed restored vision in mice with glaucoma and in primates with optic nerve damage, with improved DNA methylation patterns and visual function.
• This is a Phase 1 safety trial — not a cure you can access today. Early results are expected by late 2026 or early 2027.
• Billions of pounds are flowing into the longevity sector, with Altos Labs, Retro Biosciences, and NewLimit all pursuing variations of cellular reprogramming.

What Is Epigenetic Reprogramming — And Why Should You Care?

Your DNA is essentially fixed from birth. But the way your genes are expressed — which ones switch on, which stay silent — changes throughout your life. The system controlling this is called the epigenome: a layer of chemical markers that tell each gene what to do and when.

As you age, these markers degrade. Genes that should be active go quiet. Others that should stay off start firing. Your cells gradually lose their sense of identity and function.

Think of DNA as the original factory settings on a computer. The epigenome is the software running on top. Ageing, in this model, is what happens when that software gets corrupted over time — even though the hardware underneath is still largely intact.

Epigenetic reprogramming is the attempt to restore that software to its original state. Not by changing your DNA, but by resetting the chemical instructions that control how it’s read.

Harvard geneticist Dr David Sinclair, who co-founded Life Biosciences, calls this the Information Theory of Ageing. His argument: the loss of correct epigenetic information is a primary driver of biological ageing. The upcoming trial is a direct test of that idea — building on his team’s 2020 paper in Nature that first demonstrated the concept in mice.

If you’re interested in the broader science of biological age and what influences it, [internal link: your post on biological age vs chronological age] is a good place to start.

Who Is Being Tested — And What Are They Testing For?

The Phase 1 trial is enrolling patients with two serious eye conditions:

• Open-angle glaucoma — the most common form of glaucoma, causing gradual vision loss through damage to the optic nerve.
• Non-arteritic anterior ischemic optic neuropathy (NAION) — often called a “stroke of the eye,” which can cause sudden, permanent blindness.

Both conditions involve the death of retinal ganglion cells — the nerve fibres connecting your eye to your brain. Once lost, these cells don’t regenerate naturally. That’s precisely what makes them such a compelling test case for a therapy claiming to rejuvenate damaged tissue.

The therapy, ER-100, is delivered as a single injection directly into the eye. This local approach was chosen deliberately — it limits the therapy’s exposure to the rest of the body and makes safety monitoring far more manageable for both researchers and regulators.

Because this is Phase 1, the primary goal is safety and tolerability, not proving efficacy. Early results are expected by late 2026 or early 2027.

How Does ER-100 Actually Work?

The therapy is rooted in a Nobel Prize-winning discovery. In 2006, Japanese scientist Shinya Yamanaka showed that four specific proteins could reprogram a mature adult cell back into an embryonic-like stem cell. These are now called the Yamanaka factors.

The problem? Full reprogramming strips a cell of its identity and is strongly linked to tumour formation. You don’t want your retinal cells deciding they’d rather be stem cells.

Life Biosciences solved this by using only three of the four factors — OCT4, SOX2, and KLF4 (collectively called OSK) — and deliberately excluding the fourth, c-Myc, which is associated with uncontrolled cell growth. This partial approach rejuvenates the cell’s epigenetic markers without pushing it back to a dangerous stem-cell state.

There’s also a built-in safety mechanism. The system is doxycycline-inducible, meaning researchers can switch gene expression on or off using a common antibiotic. If anything concerning emerges during the trial, they can pause or stop the therapy entirely.

 

What Did Animal Studies Show?

The preclinical results are genuinely striking — and they’re the reason the FDA agreed to let this proceed to human trials.

In 2020, Sinclair’s team published a landmark paper in Nature showing that OSK reprogramming restored vision in mice with glaucoma-like optic nerve damage. The treatment reset the epigenetic age of retinal ganglion cells and recovered visual function that had been lost.

More recently, Life Biosciences replicated and expanded those findings in non-human primates with induced NAION-like injury. The results showed:

• Restored DNA methylation patterns — the chemical markers that define epigenetic age
• Significantly improved pattern electroretinogram responses — a direct measure of optic nerve signalling
• Increased axon density, indicating healthier nerve fibres

Beyond the eye, the company has reported early promise with ER-300, a related therapy targeting MASH (metabolic dysfunction-associated steatohepatitis) — a serious liver disease affecting roughly 5% of the global population, according to Life Biosciences. This suggests the partial reprogramming platform may work across multiple organ systems.

Can You Really Reverse Ageing — Or Is This Just Hype?

This is where the scientific community splits.

What the therapy demonstrably does in animals is restore epigenetic markers to a younger state and improve organ function. By the measure of epigenetic clocks — biological age calculators based on DNA methylation — the treated cells genuinely become younger.

But epigenetic ageing is only one piece of a larger puzzle. The therapy does not repair DNA mutations that accumulate over a lifetime — a separate hallmark of ageing entirely. It resets the regulatory layer on top of your DNA, but it can’t fix errors in the code itself.

Sinclair has described the approach as capable of a “near-total reset” for cells. Critics — including researchers who challenged his earlier work on resveratrol and NAD+ precursors — urge more caution until human data exists. If you’ve been following the NAD+ debate, [internal link: your post on NAD+ supplements and what the research actually shows] covers that in detail.

The balanced view: this is the most rigorous attempt at cellular age reversal ever undertaken in humans. It is also still in Phase 1. Both things are true.

What Are the Risks of Epigenetic Reprogramming?

The two biggest concerns with any reprogramming therapy are tumour formation and loss of cell identity. Push a cell too far back toward its embryonic state and it can either become cancerous or forget its function entirely.

Life Biosciences has addressed both through careful design:

• Excluding c-Myc removes the most cancer-associated Yamanaka factor
• Partial reprogramming rejuvenates without reverting cells to a stem-cell state
• Doxycycline control allows researchers to halt gene expression at any point
• Local delivery to the eye limits systemic exposure

Preclinical primate studies showed ER-100 was well tolerated with no systemic toxicities. But animal models don’t always predict human outcomes. Phase 1 exists precisely to surface risks that preclinical work cannot.

Who Else Is Racing to Reverse Ageing?

Life Biosciences may be first to the clinic, but it’s far from alone. Epigenetic reprogramming is now the most heavily funded area in longevity biotech. Here are the major players:

• Altos Labs — launched in 2022 with $3 billion in backing from Jeff Bezos and Yuri Milner. Has recruited Nobel laureate Shinya Yamanaka as scientific advisor and is reportedly preparing clinical trials.
• Retro Biosciences — backed by OpenAI CEO Sam Altman with $180 million, pursuing reprogramming and autophagy enhancement. Reportedly raising a $1 billion Series A at a $5 billion valuation.
• NewLimit — co-founded by Coinbase CEO Brian Armstrong. Raised $130 million in Series B in 2025, plus an additional $45 million from Eli Lilly, valuing the company at roughly $1.62 billion.

The FDA’s willingness to approve this first trial signals something broader: regulators are increasingly open to therapies targeting the upstream biological causes of ageing, rather than only treating symptoms one disease at a time. That shift matters enormously for where this field goes next.

Frequently Asked Questions

What is epigenetic reprogramming in simple terms?

It’s a process that resets the chemical switches on your genes back to a younger, healthier state — without changing your DNA itself. Think of it as restoring corrupted software to its original factory settings.

Is epigenetic age reversal available to the public?

No. ER-100 is in a Phase 1 clinical trial testing safety. Any commercial availability is likely years away, pending further trials proving both safety and efficacy.

Who can join the Life Biosciences trial?

The trial is enrolling patients with open-angle glaucoma or NAION. If you have either condition, speak with your ophthalmologist or search ClinicalTrials.gov (NCT07290244) for details.

Could this therapy eventually extend human lifespan?

That’s the long-term aspiration behind the science, but this trial isn’t testing lifespan. It’s testing safety and visual function. Broader longevity implications, if any, are years of further research away.

Stay Ahead of the Science That Actually Matters

The longevity field is moving faster than ever — and most of what you’ll read online is either hype or noise.